Major Changes in the Newly Revised Drug Administration Law

作者/编者:Huang Jianwen
作者单位:金杜律师事务所
创作年代:2019
出处/来源:金杜律师事务所
学科分类:经济法学
所属机构:金杜律师事务所
文献语种:

摘要

The newly revised Drug Administration Law (“New Law”) will come into effective on December 1, 2019. Compared with the current Drug Administration Law, significant changes with respect to the framework and the specific content have been made in the New Law. In response to the major issues in the current pharmaceutical industry, the New Law adopts several new systems, which are becoming more in line with international standards. For instance, the New Law establishes the drug marketing authorization holder system, the drug traceability system, the first accountability system, the innovation of evaluation and approval system, the unified quality management system for drug retail franchise operation and regulations of online drug sales etc. Furthermore, the New Law cancels the Good Supplying Practice and Good Manufacturing Practice certifications and adopts stricter legal liabilities. In addition, the New Law stipulates that entities or individuals importing a small amount of drugs without an importation certificate may be exempted from punishment. The New Law marks a profound change in the pharmaceutical industry. The new systems bring new challenges; the pharmaceutical enterprises need to pay close attention to the implementation rules of the New Law as they will be successively issued by the legislator in order to understand and implement the those rules. In addition, pharmaceutical enterprises will need to adjust their practical operations regarding process and management, based on the requirements of the relevant laws and regulations.

关键词: Drug Administration; Pharmaceutical Industry; China

正文

备注

本文献PDF共计6页,免费分享。

为你推荐RECOMMEND

收藏
翻译服务
下 载

该文档为付费内容,请购买后阅读全文

翻译服务

Major Changes in the Newly Revised Drug Administration Law

我们提供文献翻译服务,请填写您的联系方式,方便我们与您取得联系

提交
客服热线:13801067850 座机:010-88578296

提交成功

我们会在3个工作日内与您取得联系,请保持手机联系方式畅通